Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 5/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.42 |
| ▸ | ATM | Q13315 | 3/20 | 0.42 |
| ▸ | GAA | P10253 | 2/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 4/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19098882 | 0.94 | TAAR1 (0.45) | KMT2ASMN1; SMN2MEN1TAAR1ATM | |
| SCHEMBL19099368 | 0.90 | TAAR1 (0.44) | KMT2ASMN1; SMN2MEN1TAAR1ATM | |
| SCHEMBL19098853 | 0.89 | SMN1; SMN2 (0.38) | KMT2ASMN1; SMN2MEN1TAAR1TDP1 | |
| SCHEMBL20091071 | 0.89 | KMT2A (0.47) | KMT2ASMN1; SMN2MEN1TAAR1ATM | |
| SCHEMBL19099315 | 0.83 | TAAR1 (0.46) | KMT2ASMN1; SMN2MEN1TAAR1ATM | |
| SCHEMBL20091122 | 0.81 | KMT2A (0.48) | KMT2ASMN1; SMN2MEN1TAAR1ATM | |
| SCHEMBL19099385 | 0.80 | SLC6A2 (0.37) | — | |
| SCHEMBL19055368 | 0.78 | SMN1; SMN2 (0.39) | KMT2ASMN1; SMN2MEN1TAAR1TDP1 | |
| SCHEMBL18371893 | 0.78 | TAAR1 (0.50) | KMT2ASMN1; SMN2MEN1TAAR1ATM | |
| SCHEMBL19098914 | 0.77 | KDM4E (0.35) | KMT2ASMN1; SMN2MEN1TAAR1TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10421751-B2 | Dihydro-2H-benzo[b][1,4]oxazine sulfonamide and related compounds for use as agonists of RORγ and the treatment of disease | LYCERA CORPORATION (US) | 2019-09-24 | — | — | US | disclosed |
| US-10189777-B2 | Benzenesulfonamido and related compounds for use as agonists of RORγ and the treatment of disease | LYCERA CORPORATION (US) | 2019-01-29 | — | — | US | disclosed |
| US-20180111922-A1 | DIHYDRO-2H-BENZO[b][1,4]OXAZINE SULFONAMIDE AND RELATED COMPOUNDS FOR USE AS AGONISTS OF RORy AND THE TREATEMENT OF DISEASE | LYCERA CORPORATION | 2018-04-26 | — | — | US | disclosed |
| US-20170190659-A1 | BENZENESULFONAMIDO AND RELATED COMPOUNDS FOR USE AS AGONISTS OF RORy AND THE TREATMENT OF DISEASE | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2017-07-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180111922-A1 | DIHYDRO-2H-BENZO[b][1,4]OXAZINE SULFONAMIDE AND RELATED COMPOUNDS FOR USE AS AGONISTS OF RORy AND THE TREATEMENT OF DISEASE | RORB, RORA, RORC | KMT2A 1546/4885SMN1; SMN2 2315/4885MEN1 3786/4885 |
| US-10189777-B2 | Benzenesulfonamido and related compounds for use as agonists of RORγ and the treatment of disease | RORC, RORB, RORA | KMT2A 2706/4885SMN1; SMN2 2811/4885MEN1 4353/4885 |
| US-10421751-B2 | Dihydro-2H-benzo[b][1,4]oxazine sulfonamide and related compounds for use as agonists of RORγ and the treatment of disease | RORB, RORA, RORC | KMT2A 1579/4885SMN1; SMN2 2075/4885MEN1 4287/4885 |
| US-20170190659-A1 | BENZENESULFONAMIDO AND RELATED COMPOUNDS FOR USE AS AGONISTS OF RORy AND THE TREATMENT OF DISEASE | RORB, RORA, RORC | KMT2A 2458/4885SMN1; SMN2 3028/4885MEN1 3902/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.